These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23842101)

  • 1. Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration.
    Park UC; Shin JY; Kim SJ; Shin ES; Lee JE; McCarthy LC; Newcombe PJ; Xu CF; Chung H; Yu HG
    Retina; 2014 Feb; 34(2):288-97. PubMed ID: 23842101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.
    Cruz-Gonzalez F; Cabrillo-Estévez L; López-Valverde G; Cieza-Borrella C; Hernández-Galilea E; González-Sarmiento R
    Graefes Arch Clin Exp Ophthalmol; 2014 Mar; 252(3):469-75. PubMed ID: 24522370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.
    Smailhodzic D; Muether PS; Chen J; Kwestro A; Zhang AY; Omar A; Van de Ven JP; Keunen JE; Kirchhof B; Hoyng CB; Klevering BJ; Koenekoop RK; Fauser S; den Hollander AI
    Ophthalmology; 2012 Nov; 119(11):2304-11. PubMed ID: 22840423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.
    McKibbin M; Ali M; Bansal S; Baxter PD; West K; Williams G; Cassidy F; Inglehearn CF
    Br J Ophthalmol; 2012 Feb; 96(2):208-12. PubMed ID: 21558292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.
    Hermann MM; van Asten F; Muether PS; Smailhodzic D; Lichtner P; Hoyng CB; Kirchhof B; Grefkes C; den Hollander AI; Fauser S
    Ophthalmology; 2014 Apr; 121(4):905-10. PubMed ID: 24365177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
    Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.
    Yamashiro K; Tomita K; Tsujikawa A; Nakata I; Akagi-Kurashige Y; Miyake M; Ooto S; Tamura H; Yoshimura N
    Am J Ophthalmol; 2012 Jul; 154(1):125-36. PubMed ID: 22465368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Islam AF; Guymer RH; Baird PN
    Ophthalmology; 2013 Aug; 120(8):1641-8. PubMed ID: 23582991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration.
    Cobos E; Recalde S; Anter J; Hernandez-Sanchez M; Barreales C; Olavarrieta L; Valverde A; Suarez-Figueroa M; Cruz F; Abraldes M; Pérez-Pérez J; Fernández-Robredo P; Arias L; García-Layana A
    Acta Ophthalmol; 2018 Mar; 96(2):e201-e212. PubMed ID: 28926193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.
    Park UC; Shin JY; McCarthy LC; Kim SJ; Park JH; Chung H; Yu HG
    Mol Vis; 2014; 20():1680-94. PubMed ID: 25558172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic association with response to intravitreal ranibizumab for neovascular age-related macular degeneration in the Han Chinese population.
    Yuan D; Yuan D; Liu X; Yuan S; Xie P; Liu Q
    Ophthalmologica; 2013; 230(4):227-32. PubMed ID: 24080590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
    Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
    Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ranibizumab on high-speed indocyanine green angiography and minimum intensity projection optical coherence tomography findings in neovascular age-related macular degeneration.
    Nicholson BP; Nigam D; Toy B; Stetson PF; Agrón E; Jacobs-El N; Cunningham D; Cukras C; Wong W; Wiley H; Chew E; Ferris F; Meyerle CB
    Retina; 2015 Jan; 35(1):58-68. PubMed ID: 25077529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.
    Csaky KG; Dugel PU; Pierce AJ; Fries MA; Kelly DS; Danis RP; Wurzelmann JI; Xu CF; Hossain M; Trivedi T
    Ophthalmology; 2015 Mar; 122(3):579-88. PubMed ID: 25432081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optical coherence tomography-based ranibizumab monotherapy for retinal angiomatous proliferation in Korean patients.
    Shin JY; Yu HG
    Retina; 2014 Dec; 34(12):2359-66. PubMed ID: 25011025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population.
    Chang W; Noh DH; Sagong M; Kim IT
    Mol Vis; 2013; 19():702-9. PubMed ID: 23559864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.
    Ying GS; Huang J; Maguire MG; Jaffe GJ; Grunwald JE; Toth C; Daniel E; Klein M; Pieramici D; Wells J; Martin DF;
    Ophthalmology; 2013 Jan; 120(1):122-9. PubMed ID: 23047002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab.
    Mathew R; Richardson M; Sivaprasad S
    Am J Ophthalmol; 2013 Apr; 155(4):720-6, 726.e1. PubMed ID: 23317653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.